A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA

Brief description of study

This is a phase 3 clinical trial that compares the effectiveness of two different treatment options in patients who have undergone surgery to remove high-risk melanoma. The study will randomize participants into one of three groups: comparing the combinations of two drugs: fianlimab and cemiplimab at two different dose combinations; compared to the drug pembrolizumab and placebo. Both safety and tolerability (how your body responds) of the drug combinations will be evaluated. The goal of this study is to determine which treatment is effective in an individual's survival.

Clinical Study Identifier: s22-01563

Principal Investigator: Janice Mehnert.

Other Investigators: Nila Theresa De La Rosa, Maya Dimitrova, Kathleen M Madden, Jeffrey S. Weber.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies